Abstract
Given that an acquired immune deficiency syndrome (AIDS) vaccine is more likely to mitigate than avert human immunodeficiency virus (HIV) infection, prevention efforts are focused on the development of a microbicide to reduce the sexual transmission of HIV. In this context, a microbicide might take the form of a cream or gel applied topically prior to sexual intercourse to lower the risk of HIV transmission. The most recent advances in the development of an anti-HIV microbicide were discussed at the International Microbicides 2002 Conference, held in Antwerp, Belgium, from May 12–15, 2002. Highlights from the conference, including basic scientific, clinical, and social, political and economic aspects of microbicide development, are presented here.
Get full access to this article
View all access options for this article.